Saxenda is dead and nobody says it.

The most decisive head-to-head trial in obesity medicine was published in January 2022, and almost nobody treats it as decisive. STEP-8 put semaglutide 2.4 mg against liraglutide 3.0 mg — Wegovy against Saxenda, one company's own two products in the same room — and the result was not close. It was disqualifying.

Here is the thesis. Saxenda is not a declining product. Saxenda is a dead product: clinically superseded by a factor of roughly two and a half, commercially collapsed from its own peak, and as of December 2024 genericized in the United States. Every condition we normally use to declare a drug finished has been met.

And yet nobody says the word. I think the reason is structural rather than scientific. Pharmaceutical companies do not hold funerals for their own molecules, formularies retire drugs years after prescribers do, and medical writing has an unlimited vocabulary for a drug's arrival and almost none for its exit. So a product that lost its own maker's head-to-head trial by nine percentage points is still described, four years later, as an "option."

The minimum background. Liraglutide at 3.0 mg was approved by the FDA on December 23, 2014, as the first GLP-1 receptor agonist indicated for chronic weight management. It was a genuine advance. In the SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015, it produced roughly 8.0% mean weight loss at 56 weeks against 2.6% on placebo, with about 63% of participants losing at least 5% of body weight. Measured against what preceded it — orlistat, phentermine-topiramate, naltrexone-bupropion — that was the best pharmacotherapy obesity medicine had ever had. It required a daily subcutaneous injection.

STEP-8 was an obituary, not a comparison

Cross-trial comparison is the standing bad habit of this field, and I complain about it constantly. STEP-8 is the reason I can skip that complaint here. Published in JAMA in January 2022, it randomized adults with obesity to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg, with a shared placebo arm, one protocol, one duration.

At 68 weeks, semaglutide produced roughly 15.8% mean weight loss. Liraglutide produced roughly 6.4%. That is not a margin; it is a different order of clinical result from the same receptor. The proportion reaching at least 10% weight loss was about 70.9% on semaglutide against 25.6% on liraglutide. And the tolerability column, which people assume must favor the older and gentler drug, did not: discontinuation for adverse events ran around 3.5% on semaglutide versus roughly 12.6% on liraglutide.

Then the class kept moving. SURMOUNT-1 put tirzepatide at about 20.9% at 72 weeks in 2022. SURMOUNT-5, the tirzepatide-versus-semaglutide head-to-head reported in 2025, landed near 20.2% against 13.7%. Set liraglutide's 6.4% next to a 20% number and you are not looking at a therapeutic ladder. You are looking at a drug from a previous era that happens to share a receptor with the current one.

The commercial death happened faster than anyone admits

The market understood STEP-8 immediately, even as the literature kept hedging. Saxenda's revenue peaked around 2022 — on the order of DKK 11 billion, roughly $1.6 billion — and then fell away as Wegovy scaled, to the point where the two products stopped occupying the same conversation. By 2024, Wegovy was running at multiples of that peak while Saxenda had contracted to a rounding line in Novo Nordisk's obesity-care segment.

What makes this unusual is who did the killing. This was not a competitor displacing an incumbent. Novo Nordisk cannibalized its own franchise deliberately, ran the trial that proved the cannibalization was justified, and published it. I think that is the most underrated fact in the whole story: the company had every commercial reason to leave the comparison unrun, and ran it anyway. Pharma is rarely given credit for that, and in this case it should be.

The second force was mechanical. Weekly beats daily in adherence, always, in every therapeutic area where the comparison has been made. A weight-management therapy that requires 365 injections a year rather than 52 loses a share of its real-world effect before pharmacology enters the picture. STEP-8 measured liraglutide under supervision. Outside the trial, the gap gets wider, not narrower.

The generic arrived at a market that had already left

Then came the timing that nobody planned. Teva launched the first generic liraglutide for the Victoza indication in June 2024, and in December 2024 the FDA approved the first generic of liraglutide 3 mg — Saxenda's formulation. In the ordinary lifecycle of a successful drug, generic entry is the moment the molecule becomes accessible to everyone. Here, patent expiry arrived at a product that high-income prescribers had already stopped reaching for.

It is worth sitting with how strange that is. The molecule became cheap precisely when it stopped being the thing anyone wanted. Generic entry, normally the democratizing event in a drug's life, functioned instead as a formality performed over a product the market had abandoned two years earlier.

Why the field has no word for this

So why is Saxenda still discussed in the present tense? Three reasons, none of them clinical.

First, formularies move on a different clock than evidence. A drug written into a coverage policy in 2019 does not fall out because a 2022 trial embarrassed it; it falls out when someone reopens the policy. Where liraglutide survives on formulary, I would argue it survives as administrative sediment rather than as a therapeutic choice.

Second, step therapy can convert obsolescence into a requirement. If a payer's policy requires a trial of a cheaper agent before authorizing a newer one, the cheapest GLP-1 becomes a mandatory stop regardless of what the head-to-head says. That is a coverage-design problem, not a pharmacology one, and it keeps a superseded product in circulation by rule.

Third — and this is the part I find genuinely interesting — medicine has an elaborate ritual for a drug's approval and essentially none for its retirement. There is an FDA approval date, a launch, a label, a first-patient-dosed press release. There is no corresponding announcement that says: this molecule is finished, stop teaching it as current. Drugs simply fade, and the fading is invisible because no one is assigned to narrate it.

I should be explicit about what I am not saying. This is a market and evidence analysis, not guidance for any individual. Ozemback does not tell anyone what to take, start, stop, or switch — that belongs to a person and their licensed clinician, full stop. The claim here is about a product's standing in the field, which is a different question from any single prescription.

The strongest case that I am wrong

Take the counter-argument seriously, because it is a good one: "dead" is the wrong word for a molecule that just became affordable.

Everything above describes the United States and Western Europe, where obesity therapy is priced as a premium good and the newest agent is assumed to be reachable. That assumption does not hold across most of the world. A generic daily injectable with an established twenty-year safety record, no patent premium, and no manufacturing exclusivity is a fundamentally different proposition to a public health system in a middle-income country than a branded weekly at branded pricing. On that view, liraglutide is not dying. It is entering the phase of its life where it treats the most people it ever will.

There is a second argument, narrower but real. Liraglutide carries a pediatric weight-management indication for adolescents established through the SCALE Teens program, and daily titration gives clinicians a granularity that weekly dosing does not. In specific populations, granularity is not a consolation prize.

I find both arguments persuasive on their own terms and I still think they support my thesis rather than refute it. A drug whose entire remaining case rests on being cheap and old is not competing anymore. That is exactly what the end of a molecule's commercial life looks like: it stops being chosen and starts being defaulted to. Metformin has occupied that position for decades and nobody calls it a frontier.

Say the thing out loud

So here is what I would like the field to be able to say plainly. Saxenda's era ran from December 2014 to January 2022 — approval to STEP-8, seven years, which is a respectable run for a first-in-category product. It did the thing that mattered most: it proved that a GLP-1 receptor agonist could produce clinically meaningful weight loss in people without diabetes, which is the premise every drug in this class has been built on since.

Then it was superseded by its own successor, decisively, in a trial its own manufacturer paid for. It deserves the credit and it deserves the past tense. Pretending otherwise is not generosity toward the drug; it is a failure to describe the field accurately, and it leaves obsolete products sitting in policies and prescribing habits long after the evidence has moved.

The most underrated thing about Saxenda is that its obituary was written by the company that made it, published in a major journal, and then read by almost nobody as an obituary. Four years on, I think it is time to file it.

Ozemback — July 2026